Evidence map›Paper›PMID 42469251›Full record

ArticleNature communications2026

Sulfotransferase signaling sustains fibroblast identity and antagonizes therapeutic cardiac reprogramming.

Michaela R Romero, Sean Murphy, Yu-Ling Chang, Aashna Lamba, Sara Ancel, Alicia Llorente, James Marchant, Chun-Teng Huang, Caroline Kumsta, Peter Andersen and 10 more

Abstract read
In one paragraph

Article in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Michaela R Romero *Center for Cardiovascular and Muscular Diseases, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA, USA.
Sean Murphy *Division of Cardiology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Yu-Ling ChangCenter for Cardiovascular and Muscular Diseases, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA, USA.
Aashna LambaCenter for Cardiovascular and Muscular Diseases, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA, USA.
Sara AncelCenter for Cardiovascular and Muscular Diseases, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA, USA.
Alicia LlorenteNCI-Designated Cancer Center, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA, USA.ORCID http://orcid.org/0000-0002-6056-0566
James MarchantCenter for Cardiovascular and Muscular Diseases, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA, USA.ORCID http://orcid.org/0000-0002-9551-835X
Chun-Teng HuangViral Vector Core Facility Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA, USA.
Caroline KumstaCenter for Cardiovascular and Muscular Diseases, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA, USA.ORCID http://orcid.org/0000-0003-3839-4888
Peter AndersenDivision of Cardiology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA.ORCID http://orcid.org/0000-0003-3971-0467
Sanjeev RanadeCenter for Cardiovascular and Muscular Diseases, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA, USA.
Ahmed I MahmoudCenter for Cardiovascular and Muscular Diseases, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA, USA.ORCID http://orcid.org/0000-0003-1528-7393
Chulan KwonDivision of Cardiology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA.ORCID http://orcid.org/0000-0002-4924-2778
Hudson H FreezeCenter for Metabolic and Liver Diseases, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA, USA.ORCID http://orcid.org/0000-0001-6316-0501
Peter D AdamsNCI-Designated Cancer Center, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA, USA.ORCID http://orcid.org/0000-0002-0684-1770
Alessandra SaccoCenter for Cardiovascular and Muscular Diseases, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA, USA.ORCID http://orcid.org/0000-0003-1669-0221
Mark J RanekDivision of Cardiology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA.ORCID http://orcid.org/0000-0002-4970-8988
Brooke M EmerlingNCI-Designated Cancer Center, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA, USA.ORCID http://orcid.org/0000-0002-2168-4582
Yu Xin WangCenter for Cardiovascular and Muscular Diseases, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA, USA.ORCID http://orcid.org/0000-0001-8440-9388
Alexandre R ColasCenter for Cardiovascular and Muscular Diseases, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA, USA. acolas@sbpdiscovery.org.ORCID http://orcid.org/0000-0001-8489-0570

Funding

Tumor Microenvironment and Cancer ImmunologyP30CA030199 · NCI · SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE · PI ELENA B PASQUALE · 1985 to 2026
$107.2M
Project 3 (Mercola)P01HL141084 · NHLBI · STANFORD UNIVERSITY · PI Joseph C. Wu · 2019 to 2026
$21.1M
New Congenital Disorders of Glycosylation: Therapy and ModelsR01DK099551 · NIDDK · SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE · PI Hudson H. Freeze · 2014 to 2026
$6.7M
Defining chromostasis - a candidate regulator of healthy aging and longevityR01AG071464 · NIA · SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE · PI ADAMS, PETER D. · 2020 to 2024
$3.9M
Targeting Dysregulated Maturation Program in PSC-CardiomyocytesR01HL171205 · NHLBI · JOHNS HOPKINS UNIVERSITY · PI Chulan Kwon · 2024 to 2026
$2.2M
Discovery of Small Molecule Promoters of Cardiomyocyte Proliferation to Restore Cardiac Performance in DiseaseR01HL148827 · NHLBI · SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE · PI COLAS, ALEXANDRE ROMAIN · 2019 to 2022
$2.0M
Discovery of small molecule regulators of atrial cardiomyocyte action potential duration to restore normal cardiac rhythm in atrial fibrillationR01HL153645 · NHLBI · SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE · PI COLAS, ALEXANDRE ROMAIN · 2021 to 2024
$1.9M
Beckman Coulter Biomek i7 Hybrid automated workstationS10OD036254 · OD · SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE · PI HUANG, CHUN-TENG · 2024 to 2024
$594k
NCI NIH HHS P30 CA030199NHLBI NIH HHS P01 HL141084NHLBI NIH HHS R01 HL148827NHLBI NIH HHS R01 HL153645NHLBI NIH HHS R01 HL171205NIA NIH HHS R01 AG071464NIDDK NIH HHS R01 DK099551NIH HHS S10 OD036254U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute (NHLBI) HL141084U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute (NHLBI) HL148827U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute (NHLBI) HL153645
6 · The paper itself

Abstract

Differentiated cells maintain their identity through active mechanisms that suppress alternative cell fates, but disrupting these barriers can enhance direct reprogramming for organ repair. Among the regulators of cell fate stability, glycosylation-associated genes have emerged as barriers to cardiac reprogramming. Here we show that carbohydrate sulfotransferases are central fate-stabilizing regulators, with CHST7 acting through CD44 to control nuclear JUNB levels, chromatin binding, and downstream transcriptional activity. Integrated RNA-seq and ATAC-seq analyses reveal that CHST7 maintains open chromatin at JUNB- and CTCF-enriched loci while restricting accessibility at MEF2C-enriched regions, collectively reinforcing fibroblast identity and suppressing cardiac fate acquisition. We further identify PIP4K2C as a downstream effector whose inhibition enhances cardiac reprogramming efficiency and improves myocardial repair in vivo. These findings define a sulfotransferase-dependent barrier to cell fate conversion with therapeutic implications for heart regeneration.

Indexed as

Cellular ReprogrammingFibroblastsSulfotransferasesAnimalsCarbohydrate SulfotransferasesCell DifferentiationChromatinHumansHyaluronan ReceptorsMEF2 Transcription FactorsMiceMyocardiumMyocytes, CardiacSignal TransductionCarbohydrate SulfotransferasesChromatinHyaluronan ReceptorsMEF2 Transcription FactorsSulfotransferases

Identifiers

PMID42469251
PMCPMC13493861

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.